Kala Pharmaceuticals (NASDAQ: KALA) and CTI BioPharma (NASDAQ:CTIC) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, valuation, analyst recommendations and earnings.
Earnings and Valuation
This table compares Kala Pharmaceuticals and CTI BioPharma’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|Kala Pharmaceuticals||$40,000.00||12,517.46||-$33.16 million||N/A||N/A|
|CTI BioPharma||$57.40 million||2.17||-$52.00 million||($1.19)||-2.44|
Kala Pharmaceuticals has higher revenue, but lower earnings than CTI BioPharma.
This table compares Kala Pharmaceuticals and CTI BioPharma’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional & Insider Ownership
22.2% of Kala Pharmaceuticals shares are owned by institutional investors. Comparatively, 43.9% of CTI BioPharma shares are owned by institutional investors. 8.1% of CTI BioPharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
This is a breakdown of current recommendations for Kala Pharmaceuticals and CTI BioPharma, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Kala Pharmaceuticals currently has a consensus target price of $36.80, indicating a potential upside of 80.22%. CTI BioPharma has a consensus target price of $7.50, indicating a potential upside of 158.62%. Given CTI BioPharma’s higher possible upside, analysts clearly believe CTI BioPharma is more favorable than Kala Pharmaceuticals.
Kala Pharmaceuticals beats CTI BioPharma on 6 of the 10 factors compared between the two stocks.
About Kala Pharmaceuticals
Kala Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles, or MPP, technology. The Company’s initial focus is on the treatment of eye diseases. The Company’s product candidate includes KPI-121 1%, KPI-121 0.25% and MPP rTKI Program. The Company has completed two Phase III clinical trials for KPI-121 1% . The KPI-121 0.25% is the Company’s product candidate for temporary relief of signs and symptoms of dry eye disease. KPI-121 1% is the twice-a-day product candidate for treatment of post-operative inflammation and pain following ocular surgery. MPP rTKI Program is therapies for retinal diseases that should be injected directly into the patient’s eye, often at monthly intervals.
About CTI BioPharma
CTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). It is also engaged in evaluating pacritinib for the treatment of adult patients with myelofibrosis. Its earlier stage product candidate, tosedostat, is an oral, once-daily aminopeptidase inhibitor that has demonstrated responses in patients with acute myeloid leukemia (AML). It also evaluates its pipeline candidate paclitaxel poliglumex (Opaxio), which targets solid tumors. It is evaluating Opaxio through cooperative group sponsored trials and investigator-sponsored trials (ISTs), such as the ongoing maintenance therapy trial in patients with ovarian cancer.
Receive News & Ratings for Kala Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.